Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 30, 2017

Primary Completion Date

October 26, 2020

Study Completion Date

October 26, 2020

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

peginterferon beta-1a

SC every 2 weeks

DRUG

interferon beta-1a

Per Summary of Product Characteristics (SMPC)

DRUG

interferon beta-1b

Per SMPC

Trial Locations (15)

2720-276

Hospital Fernando Fonseca, Amadora

4710-243

Hospital de Braga, Braga

6200-251

Centro Hospitalar Cova da Beira, Covilha

7000-811

Hospital Evora, Evora

9004-514

Hospital Dr. Nelio Mendonça, Funchal

4835-044

Hospital da Senhora da Oliveira, Guimarães

2410-197

Centro Hospitalar de Leiria, Leiria

1349-019

Hospital Egas Moniz, Lisbon

1500-650

Hospital da Luz, Lisbon

1649-035

Centro Hospitalar Lisboa Norte - Hosp Santa Maria, Lisbon

2674-514

Hospital Beatriz Ângelo, EPE, Loures

4464-513

ULS Matosinhos, Matosinhos Municipality

4099-001

Hospital Santo Antonio, Porto

4520-211

Hospital de Sao Sebastiao, Santa Maria da Feira

4904-858

Hospital Viana do Castelo, Viana do Castelo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY